Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 22, 165-166 (2023)



We thank the Health and Environmental Sciences Institute (HESI) of the Genetic Toxicology Technical Committee (GTTC) members for their scientific input. All authors are members of the HESI GTTC. This article reflects the views of the authors and does not necessarily reflect the official views or policy of the US Food and Drug Administration, the National Institutes of Health, or the US government.


  1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).

    Article  PubMed  Google Scholar 

  2. Salk, J. J., Schmitt, M. W. & Loeb, L. A. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat. Rev. Genet. 19, 269–285, (2018).

    Article  PubMed  Google Scholar 

  3. Wang, Y. et al. Genetic toxicity testing using human in vitro organotypic airway cultures: assessing DNA damage with the CometChip and mutagenesis by Duplex Sequencing. Environ. Mol. Mutagen. 62, 306–318 (2021).

    Article  PubMed  Google Scholar 

  4. Valentine, C. C. III et al. Direct quantification of in vivo mutagenesis and carcinogenesis using duplex sequencing. Proc. Natl Acad. Sci. USA 117, 33414–33425 (2020).

    Article  PubMed  Google Scholar 

  5. Fielden, M. R. et al. Modernizing human cancer risk assessment of therapeutics. Trends Pharmacol. Sci. 39, 232–247 (2018).

    Article  PubMed  Google Scholar 

Download references

Competing Interests

J.J.S. is an employee and equity holder at TwinStrand Biosciences Inc., and is an author on one or more duplex sequencing-related patents. R.C., J.E., P.A.E., T.H. Jr, D.K., A.M.L., J.J.S., S.Z. and S.M. are employed by companies that may be engaged in using error-corrected sequencing.

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links